Shenhuang granules for adults with sepsis
Official title: Evidence-based Evaluation and Mechanism of Shenhuang Granules in the Treatment of Sepsis: a Randomized, Double-blind, Placebo-controlled, Effective Clinical Trial
Run by The First Affiliated Hospital of Zhejiang Chinese Medical University · NCT06514339 · Data updated 2026-11-12
This trial will test whether Shenhuang granules can improve recovery and survival in adults with sepsis.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 410 (estimated) |
| Sponsor | The First Affiliated Hospital of Zhejiang Chinese Medical University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | July 1, 2024 |
| Main results expected | March 1, 2026 |
| Study ends | July 1, 2026 |
| Registry record updated | August 22, 2025 |
| Trial ID | NCT06514339 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) diagnosed with sepsis by Sepsis-3 criteria who can give informed consent and do not meet the exclusion criteria are ideal candidates.
✕Probably not a fit
Patients with very severe organ dysfunction (e.g., SOFA ≥15, expected death within 48 hours), significant liver or kidney failure, recent high-dose immunosuppression or chemotherapy, pregnancy, or contraindications to traditional Chinese medicine are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Hospitalized adults with sepsis will receive either Shenhuang granules or a matching placebo alongside standard care, with clinical staff collecting baseline and follow-up data. The primary outcome is 28-day mortality, and secondary outcomes include ICU/hospital length of stay, costs, ventilation-free days, TCM symptom scores, and organ function scores (SOFA, APACHE II). Blood tests will measure inflammatory markers, organ function, coagulation, and immune cell counts, and selected participants may provide samples for metabolomic analysis. Safety monitoring will record adverse events and allergic reactions throughout the study.
Why it matters
Potential benefit: If effective, the treatment could reduce 28-day mortality and improve organ function and immune balance in patients with sepsis.
How similar studies have gone: There is limited clinical evidence specific to Shenhuang granules in sepsis; preclinical studies and small clinical reports suggest immune-modulating effects but no large randomized trials have yet shown clear mortality benefit.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years old * Meet the diagnostic criteria of sepsis 3.0 guidelines * Sign informed consent. Exclusion Criteria: * Liver or kidney single SOFA score ≥3 points of liver and kidney dysfunction * Death is expected within 48 hours, or SOFA≥15 points, or APACHE II ≥30 points, or the patient refuses active treatment * Patients with allergic reactions to traditional Chinese medicine * Patients treated with chemotherapy or radiotherapy or high-dose immunosuppressants within the last 1 month * Participants in other clinical trials at the same time or within 30 days * Pregnant and lactating women * Patients with severe gastrointestinal bleeding, intestinal obstruction, or severe intraperitoneal pressure elevation (IAP≥20mmHg).
Where it's running
-
First Affiliated Hospital of Zhejiang Chinese Medical University
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Wu JianNong, doctor
- Email: 13777571598@163.com
- Phone: 13777571598
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care
This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.
-
Early detection of sepsis-related blood clotting problems in severe burn patients
This study tests how well the JAAM-2 score can detect sepsis-induced coagulopathy early in adults with severe burns who develop sepsis in the ICU.
-
Neutrophil EMR3 as a biomarker for sepsis in ICU patients
Researchers will test whether measuring EMR3 on neutrophils helps diagnose sepsis, monitor progression, and predict outcomes in adults in Chinese ICUs.
-
Thymalfasin added to standard care for adults with sepsis and immune dysfunction
This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.
-
Multicenter group study of sepsis and ARDS in China
This study tests how sepsis and ARDS differ among adults across several Chinese hospitals and builds a biobank to understand why some patients do better or worse.
-
Non-invasive hemodynamic guidance for sepsis care on medical wards
This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.